UTVRDJIVANJE HUMANIH PAPILOMA VIRUSA SA SA ABNORMLNIM CITOLOŠKIM NALAZOM KOD ADOLESCENTKINJA U HRVATSKOJ
DOI:
https://doi.org/10.46793/PP170207011LKljučne reči:
Cervikalna intraepitelna neoplazija, Humani papiloma virusi, AdolescentiApstrakt
Povezanost određenih humanih papiloma virusa (HPV) i cervikalne intraepitelne neoplazije (CIN) dobro je dokumentirana, no još uvijek nije poznata među hrvatskim adolescentkinjama. Žene u dobi od 15 do 20 godina s abnormalnim citomorfološkim brisom (CIN I-IV) testirane su na prisustvo HPV-a. Konsenzus i posebne početnice korišteni su u lančanoj reakciji polimeraze (PCR za otkrivanje najčešćih tipova: 6, 11, 16, 18, 31 i 33. Osim niskorizičnog HPV-a 6/11 (25,8%), najčešće utvrđeni bili su visokorizični tipovi HPV-a, tip 16 (20,2%) i 31 (17,8%). Uopšteno, stopa pozitivnosti na HPV značajno opada s godinama. Prisutnost HPV DNK znatno se povećala s 35,5 na 61,1% uz ozbiljnost cervikalne intraepitelne neoplazije (CIN I-IV). HPV tip 6/11 snažno je povezan s CIN I (33,8%), HPV tip 31 s CIN II (22,9%) i HPV tip 16 s CIN III (50%).
Reference
Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and Transmission dynamics of genital HPV infection. Vaccine 2006; 24 (suppl 3): S52-S61.
Rousseau MC, Pereira JS, Prado JC, et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184: 1508-1517.
Bosch FX, de SanJose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexuality transmitted deseases among American Youth, 2000. Perspect Sex Reprod Health 2004; 36: 11-19.
Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31: 748-752.
Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human Papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2): 1-24.
Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010; 341:c3493.
Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Prev Med 2011; 53(suppl 1):S29-S35.
Read TRH, Hocking JS, Chen MY, et al. The near disapperance of genita Warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87: 544-547.
Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine in all HPV-associated genital diseas in young Women. J Natl Cancer Inst 2010; 102:325-339.
Manos MM, Ting Y, Wright DK, et al. The use of polymerase chain Reaction amplification for the detection of genital human Papillomaviruses. In: Furth M, Greaves M (eds), Molecular diagnostics of Human cancer: Cancer cells. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989: 209-214.
Novelli G, Gennarelli M, de Santis, et al. Inosinecontaining primers in human papillomavirus detection by polymerase chain reaction. Biomed Pharmacother 1992; 46: 167-169.
Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increase susceptibility to bladder cancer. J Nat Cancer Inst 1993; 85: 1159-1164.
van den Brule AJC, Meijer CLJ, Bakels V, et al. Rapid detection of human Papillomavirus in cervical scrapes by combined general primer-mediated and typespecific polymerase chain reaction. J Clin Microbiol 1990; 28: 2739-2743.
Poulsen S. The Danish HPV programme: A success story- vaccination by general practitioners. Presented at: The Eurogin 2011 International Congress (abstract SS4-11); 2011, Lisabon.
Oliphant J, Perkins N. Impact of the huuman papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011; 124: 51-58.
Grce M, Magdić L, Kocijan I, Pavelić K. Increase of genital human papillomavirus infection among men and women in Croatia. Anticancer Res 1996; 16: 1039-1042.
Hu D, Goldie S. The economic burden of noncervical human papilloma- virus disease in the United States. Am J Obstet Gynecol 2008; 198: 500- 507.
Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 2010; 341: c3493.
Roggendorf H. Erste Erfahrungen zur Akzeptanz der HPV- Impfung Durchimpfungsrate eines Jahrgangs in einer Groβstadt 1 Jahr nach Impfempfehlung durch die STIKO. Monatsschrift Kinderheilkunde 2009; 10: 982-985.
Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: Rates, predictors, and reasons for non vaccination. Matern Child Health J 2012. Published online ahead of print June 23, 2012. PMID: 22729660.
Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: Impact of infection with human immunodefici ency virus. Arch Pediatr Adolesc Med 2000; 154: 127-134.
Vaccarella S, Herrero R, Snijders PJ, et al. Smoking and human papilloma virus infection: Pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008; 37: 536- 546.
Satterwhite CL, Torrone E, Meites EF et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40: 187-193.
Tilson EC, Sanchez V, Ford CL, et al. Barriers to asymptomatic screening and other STD services for adolescents and young adults: focus group discussions. Bmc Public Health 2004; 4:21.
Centers for Disease Control, Prevention (CDC). Sexually transmitted diseases treatment guidelines 2010. Morb Mortal Wkly Rep 2010; 59 (RR-12): 1-110.
